Pacira BioSciences, Inc.
PCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 3.9% | 1.2% | 23.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 75.7% | 72.6% | 70.1% | 74.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | $0 | $0 |
| % Margin | -10.5% | 13% | 9% | 16.6% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -14.2% | 6.2% | 2.4% | 7.8% |
| EPS | -2.15 | 0.91 | 0.35 | 0.95 |
| % Growth | -336.3% | 160% | -63.2% | – |
| EPS Diluted | -2.15 | 0.89 | 0.34 | 0.92 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 4.2% | 22.9% | 21.1% | 21% |